-
In-form Fernandez reaches Tokyo final
-
Marc Marquez on front row at Malaysian MotoGP as Martin ruled out
-
James, Maxey fuel 76ers over Knicks in NBA Cup thriller
-
Injured Martin out of Malaysian MotoGP in big title blow
-
High-speed, high-risk Route du Rhum yacht race sets off Sunday
-
US, S.Korea, Japan vow 'complete' N.Korea denuclearization
-
Fears of violence as France braces for Halloween protests
-
Nations commit to get nature goals back on track
-
OKC's Holmgren to miss at least eight weeks as Thunder injury woes deepen
-
US oil companies aim to squeeze more out of refineries
-
'Not very smart' - Verstappen slams Red Bull stable-mate after clash
-
Leclerc quickest in Mexico GP practice
-
Trump admin approves potential Patriot missiles sale to Ukraine
-
Polish riot police deployed as deposed court chief sets off crisis
-
Sun Goddess wins at Breeders' Cup, O'Brien leads Baffert
-
Young Canadians focus on mental health at key climate trial
-
Nations agree push to get nature goals on track
-
'Breath of fresh air' truce brings hope to Ukraine's ravaged Kherson
-
Leclerc shows practice pace as Antonelli prowls in Mexico
-
British king reflects on colonial atrocities in Guyana
-
Trump, Milei under pressure to explain Bolsonaro flight from Brazil
-
Nations agree crucial texts in overtime at UN nature summit
-
Hakimi bags hat-trick as Paris Saint-Germain rip Le Havre to pieces
-
NBA Trail Blazers lose guard Morant for four weeks
-
Polish riot police deployed after court chief suspended
-
UN nature summit in extra time as nations grapple for deal
-
Emery's focus fully on Fulham despite Barcelona tie
-
Complaints upheld against Swiss TV commentary on Israeli bobsleigher
-
Reigning champs chase history in New York Marathon
-
Tielemans glad Man Utd sticking with Carrick
-
Monaco taken off global money-laundering 'grey list'
-
Scottish police probe Andrew, Epstein stay at royal castle: UK media
-
Canada, EU launch new alliance with deals on Ukraine, minerals, AI
-
Medvedev into Vienna semis and books ATP Finals place
-
Tears, fear, anger: relatives of Spain train crash dead await fate
-
UN nature talks in extra time as nations struggle to reach deal
-
Spurs get Maddison boost ahead of Palace clash
-
Meta settles, leaving Snap sole defendant in new social media trial
-
French authorities fear new street violence at Halloween protests
-
Chelsea manager Alonso dismisses talk of Estevao loan deal
-
Rickelton, Mulder centuries lift South Africa's chances in Test decider
-
Thousands of students, workers hold peaceful protests in Italy
-
Maresca adamant Donnarumma can be dropped but first name selected
-
Iraola glad to raise Liverpool fans' hopes but says hard work ahead
-
EU and Canada to 'withstand shocks together' with new alliance
-
Pope Leo makes history with US midterm vote
-
Flick praises Yamal 'mentality' after missing out on Ballon d'Or
-
Arsenal boss Arteta fires 'Disneyland' warning at Dowman after Fleetwood red card
-
Binance heist: How were cryptocurrency billions stolen?
-
Russia's ice hockey stars come in from the cold after CAS ruling
Abortion pill under threat in Texas court case
US abortion opponents are hoping for a national ban on a widely used abortion pill when their lawsuit against government drug regulators is argued Wednesday in the Texas court of a deeply conservative judge believed to be sympathetic to their cause.
Galvanized after the US Supreme Court ended the nationwide right to abortion last June, anti-abortion forces are now targeting the prescription drug mifepristone in their campaign to win a total ban on the practice.
The suit against the US Food and Drug Administration (FDA) aims at a pill involved in 53 percent of all abortions in the United States, or more than a half-million every year.
While the FDA has never been challenged like this before on its approval of a drug that has proven safe and effective, the plaintiffs, a coalition of anti-abortion groups, believe they can win a national freeze on distribution of mifepristone.
Presiding over the case in federal court in Amarillo, Texas will be Judge Matthew Kacsmaryk, a deeply conservative Christian with a personal history of opposition to abortion and a court record of favoring right-wing causes.
The case ended up in his court via what critics call "judge-shopping," in which plaintiffs take legal action in a district where the judge has a history of rulings that support their case.
- Record of safety -
One component of a two-drug regimen used for medication abortion, mifepristone can be used in the United States up to 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying the approval of mifepristone "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with its use.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
- Already banned in some states -
Currently, some 15 states have laws restricting access to mifepristone by requiring a physician provide it, according to the Guttmacher Institute, a reproductive health policy and research group. Abortion care has halted in another 13 states after the Supreme Court overturned the long-established constitutional right last June.
The Texas suit seeks to block mifepristone nationally by overturning the FDA's approval of the drug, and asks Kacsmaryk to first suspend the approval via injunction -- an effective ban -- while the lawsuit proceeds through his court.
Abortion rights groups say a ruling blocking mifepristone would be as earth-shaking as the Supreme Court's ruling last year.
"Access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
If Kacsmaryk does rule for a temporary ban on mifepristone, the FDA would likely immediately appeal it, on the basis of the drug's history and its own authority to regulate pharmaceuticals.
But abortion rights advocates were preparing for the worst.
"It seems unbelievable that a lone judge in Texas could make a ruling that would impact a product that has been FDA approved and safely marketed for more than two decades," said Elisa Wells, co-founder of Plan C, which helps people access medical abortions.
C.Kovalenko--BTB